A Phase 3 Study of HS-20094 in Patients With T2DM

NCT07156539 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing the safety and effectiveness of the experimental drug HS-20094 in adults with type 2 diabetes to see how it affects their blood sugar levels over time.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 546 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-09 · est. completion 2027-05

Where 2 sites · China

What this study is testing ClinicalTrials.gov NCT07156539 ↗

Description as written by the study sponsor.

The study is being conducted to evaluate the efficacy and safety of HS-20094 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Dulaglutide QW for 44 weeks and 52 weeks.

Treatments tested

HS-20094 Injection Drug

HS-20094 injected subcutaneously once weekly
Dulaglutide Injection Drug

Dulaglutide injected subcutaneously once weekly

Main thing measured	Change in HbA1c
Sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07156539 ↗